Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

Abstract Background Consensus is lacking regarding the optimal salvage therapy for patients with follicular lymphoma who relapse after or are refractory to immunochemotherapy. Methods This phase II trial evaluated the efficacy and safety of response‐adapted therapy with rituximab, bendamustine, mito...

Full description

Bibliographic Details
Main Authors: Francisco‐Javier Peñalver, José‐Antonio Márquez, Soledad Durán, Pilar Giraldo, Alejandro Martín, Carlos Montalbán, Juan‐Manuel Sancho, María‐José Ramírez, María‐José Terol, Francisco‐Javier Capote, Antonio Gutiérrez, Blanca Sánchez, Andrés López, Antonio Salar, Gil Rodríguez‐Caravaca, Miguel Canales, María‐Dolores Caballero, on behalf of GELTAMO (The Spanish Lymphoma Cooperative Group)
Format: Article
Language:English
Published: Wiley 2019-11-01
Series:Cancer Medicine
Subjects:
bendamustine
follicular lymphoma
immunochemotherapy
refractory
relapsed
Online Access:https://doi.org/10.1002/cam4.2555

Internet

https://doi.org/10.1002/cam4.2555

Similar Items